Nutriband Inc.
NASDAQ:NTRBBiotechnology
+$0.85 today
- Market cap
- $58.59M
- Beta
- 1.97
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.66
Volume 0.03M
Average 0.01M
NTRB Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Nutriband Inc.NASDAQ: NTRB
Depreciation & Amortization · Q1 FY2026 · quarter ended Apr 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $34.18K fell 40.5% year over year, behind the -37.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.7% from the prior quarter. Over 3 fiscal years it compounded at -19.3% a year.
Context
- Depreciation & amortization amounted to 9.5% of revenue in FY2025, down 3.8 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -40.5% toward the trailing-twelve-month pace of -37.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 193.8K USD
- Year-over-year change
- -32.0%
- 4-year CAGR
- -11.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-31 | 193.8K | -32.0% |
| FY2024 | 2025-01-31 | 285.05K | -0.9% |
| FY2023 | 2024-01-31 | 287.72K | -22.0% |
| FY2022 | 2023-01-31 | 368.96K | +15.9% |
| FY2021 | 2022-01-31 | 318.26K | — |
Depreciation & Amortization vs competitors
How NTRB compares with its peers on the latest reported figures
- NTRB's LTM Apr 2026 depreciation & amortization of $170.49K is the 7th largest of the 9 companies compared; the peer median is $1.39M.
- Its year-over-year change of -37.6% is the 6th highest of 7, against a peer median of -2.9%.
- Depreciation & amortization amounts to 9.5% of revenue for NTRB, versus a peer median of 31.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.17M | +4.4% | -20.7% | 7.8% | |
| LTM Mar 2026 | $3.86M | -37.8% | -3.9% | — | |
| LTM Mar 2026 | $2.88M | -18.4% | -17.7% | 31.5% | |
| LTM Mar 2026 | $1.58M | -10.2% | -13.6% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.21M | +8.3% | +36.2% | — |
| LTM Jun 2024 | $515.94K | — | -25.9% | 63.2% | |
| LTM Apr 2026 | $170.49K | -37.6% | -19.3% | 9.5% | |
| LTM Mar 2026 | $94.69K | +12.5% | +13.6% | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding NTRB) | $1.39M | -2.9% | -13.6% | 31.5% | |
Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Jan 2024 | FY2024 Jan 2025 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Net Income | (6.18M) | (4.48M) | (5.49M) | (10.48M) | (8.23M) |
| Depreciation & Amortization | 318.26K | 368.96K | 287.72K | 285.05K | 193.8K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 897.83K | 732.13K | 742.7K | 1.54M | 104.4K |
| Change in Working Capital | (541.38K) | (219.32K) | 223.22K | 34.09K | 126.81K |
| Accounts Receivables | 42.97K | (41.67K) | (153.97K) | 74.8K | (44.56K) |
| Inventory | (78.8K) | (97.69K) | 60.73K | (43.44K) | 94.05K |
| Accounts Payables | (145.26K) | (104.86K) | 198.89K | 23.61K | 120.94K |
| Other Working Capital | (360.29K) | 24.9K | 117.57K | (20.89K) | (43.63K) |
| Other Non-Cash Items | 2.23M | 614.51K | 704.17K | 3.99M | 2.67M |
| Operating Cash Flow | (2.81M) | (2.99M) | (3.53M) | (4.63M) | (5.13M) |
| Capital Expenditures | (81.6K) | (79.3K) | (51.76K) | (92.04K) | (5.32K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (81.6K) | (79.3K) | 0 | 0 | 0 |
| Investing Cash Flow | (81.6K) | (79.3K) | (51.76K) | (92.04K) | (5.32K) |
| Debt Repayment | (1.63M) | (17.8K) | 2.09M | 8.69M | (21.62K) |
| Common Stock Issued | 6.42M | 0 | 2.61M | 8.41M | 5.42M |
| Common Stock Repurchased | (104.47K) | (119.01K) | 0 | (149K) | 0 |
| Dividends Paid | (196.59K) | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.14M | 296.88K | 0 | 69 | 0 |
| Financing Cash Flow | 7.63M | 160.07K | 2.09M | 8.54M | 5.4M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 4.74M | (2.91M) | (1.49M) | 3.82M | 263.14K |
| Free Cash Flow | (2.89M) | (3.07M) | (3.58M) | (4.72M) | (5.13M) |
Nutriband Inc.
NASDAQ:NTRB
Intrinsic Alpha fair value
Locked
Current Price
$4.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.